Plain-English translation of NCT06751940 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a neoantigen-loaded dendritic cell vaccine combined with conventional second-line chemotherapy for people whose colorectal cancer has stopped responding to first-line treatment. The vaccine is personalized for each patient—doctors will analyze your tumor's unique mutations and create a custom vaccine designed to train your immune system to recognize and attack your cancer cells. You'll receive this personalized vaccine alongside standard chemotherapy over 21 weeks.
When colorectal cancer stops responding to first-line chemotherapy, treatment options become limited and outcomes worsen. This trial explores whether a personalized vaccine that harnesses your own immune system, combined with conventional second-line therapy, might offer better results than standard treatment alone.
You likely qualify if…
You likely don't qualify if…
You will undergo blood tests and imaging scans so doctors can analyze your tumor and design your personalized vaccine. Over 21 weeks, you'll receive standard second-line chemotherapy along with 10 injections of your custom vaccine under the skin. After treatment ends, you'll return for follow-up visits every 6 weeks, which will include blood work, physical exams, scans, and other assessments to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China